Buprenorphinum, a sublingual medicament used to treat patients addicted to or dependent on narcotics, is sold under the brand names Subutex and Temgesic. This medicament reduces the patients withdrawal symptoms by retarding the patients perceived urgency of seeking opioid substances. Being a narcotic itself, it is widely used by doctors, medical professionals and medical practitioners as part of a therapeurinary tract infectionc regimen of narcotic dependents.
The main effect during administration is a long lasting analgesic effect, which is a benefit for most patients because of a longer consistent therapy management. Other benefits of this medicament are its low medicament interactions, low profile administration through the sublingual or transdermal routes, least amount of renal accumulation, and its lack of any type of immune system suppressant. This lessens the side effects experienced by most patients.
Those with intense to moderately rated chronic pain should be treated with Buprenorphinum, especially those who are set to have an operation. This medicament is a common peri-operative medicament urinary tract infectionlized among cancer patients.
Those suffering from depression or psychosis may be treated successfully with Buprenorphinum. However, psychological distress has yet to be included in the official list of tested and approved indications for this medicament. The conflict between successful therapeurinary tract infectionc claims of the medicament over such ailments and the actual approval in the medical field elicits debates and lands the medicament in a gray area in this regard.
This medicament is available in both 2 and 8 milligram variants, wherein adults whose age is 13 years and above may be administered 1 milliliter of the medicament containing .3mg of Buprenorphinum. It is usually administered through intramuscular route and is given in a slow push, lasting up to 2 minutes. Intervals prescribed by the physician may go as often as every 6 hours.
For children, the usual dose would be 2 to 6 micrograms per kilo of body weight given every 4 hours. Some doctors may give the medicament at 6-hour intervals for better body compliance.
In a clinical test of about 1,133 patients treated with this medicament, about two thirds of the population showed side effects overall, with different effects. Even with the high level of side effects, the intensity of the side effects was minimal or negligible. As an added note, those patients who were successfully treated were easily roused back to an alert state.
Common side effects occurring with the test sample population were Nausea and Vertigo, occurring in 5 to 10% of the population. Other symptoms include sweating, diaphoresis, hypotension, emesis, cephalalgia, and hypoventilation. Let your doctor know if you experience any of these symptoms.
Adverse side effects that occur in rare occasions include loss of appetite, agitation, diarrhoea, urticaria, and neuromuscular impairment as evidenced by occasional convulsions and muscle twitching. Consult your doctor immediately if any of these symptoms arise.
Negative drug interaction is documented with CYP3A4 isozymes in the body, which may lower the clearance of the medicament in the bloodstream.
As for CYP3A4 inducers such as rifampin, phenytoin, and phenytoin, they may actually help clearance of the medicament from the body.
Women who are pregnant, plan to become pregnant or become pregnant during treatment should take special precaurinary tract infectionon with this medicament as it may affect normal fetal growth.
Buprenorphinum has the following structural formula:
• Molecular formula of buprenorphinum is C29H41NO4
©2007-2017 Medicalook.com All rights reserved